IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 228 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,046,474 | +105.7% | 3,087,137 | +218.2% | 0.00% | +200.0% |
| Q2 2023 | $6,830,088 | +30.7% | 970,183 | +13.4% | 0.00% | 0.0% |
| Q1 2023 | $5,226,341 | +141.3% | 855,375 | +152.4% | 0.00% | – |
| Q4 2022 | $2,165,878 | -74.7% | 338,948 | -62.1% | 0.00% | -100.0% |
| Q3 2022 | $8,577,000 | +7.9% | 895,323 | +24.3% | 0.00% | 0.0% |
| Q2 2022 | $7,951,000 | -40.8% | 720,180 | -10.7% | 0.00% | 0.0% |
| Q1 2022 | $13,431,000 | -75.8% | 806,653 | -72.3% | 0.00% | 0.0% |
| Q4 2021 | $55,610,000 | +98.6% | 2,913,000 | +156.5% | 0.00% | -50.0% |
| Q3 2021 | $28,003,000 | -16.5% | 1,135,539 | -11.9% | 0.00% | -20.0% |
| Q2 2021 | $33,541,000 | +169.0% | 1,289,048 | +227.3% | 0.01% | +150.0% |
| Q1 2021 | $12,471,000 | -87.6% | 393,889 | -81.8% | 0.00% | -77.8% |
| Q4 2020 | $100,550,000 | +148.7% | 2,167,018 | +76.4% | 0.01% | +12.5% |
| Q3 2020 | $40,429,000 | +13.3% | 1,228,137 | -5.5% | 0.01% | -11.1% |
| Q2 2020 | $35,692,000 | -15.5% | 1,300,285 | -7.9% | 0.01% | -30.8% |
| Q1 2020 | $42,246,000 | +209.8% | 1,411,261 | +186.5% | 0.01% | +225.0% |
| Q4 2019 | $13,635,000 | +114.7% | 492,600 | +41.2% | 0.00% | +33.3% |
| Q3 2019 | $6,350,000 | -56.3% | 348,984 | -41.1% | 0.00% | +50.0% |
| Q2 2019 | $14,542,000 | +1061.5% | 593,001 | +350.6% | 0.00% | – |
| Q1 2019 | $1,252,000 | +10.4% | 131,600 | +2.7% | 0.00% | – |
| Q4 2018 | $1,134,000 | -75.8% | 128,200 | -69.2% | 0.00% | -100.0% |
| Q3 2018 | $4,686,000 | +69.4% | 416,500 | +92.7% | 0.00% | – |
| Q2 2018 | $2,766,000 | -28.2% | 216,100 | -5.3% | 0.00% | -100.0% |
| Q1 2018 | $3,854,000 | +237.8% | 228,100 | +59.9% | 0.00% | – |
| Q4 2017 | $1,141,000 | -79.9% | 142,687 | -80.5% | 0.00% | -100.0% |
| Q3 2017 | $5,683,000 | +276.1% | 733,173 | +256.6% | 0.00% | – |
| Q2 2017 | $1,511,000 | – | 205,599 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |